GW Henssler & Associates Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

GW Henssler & Associates Ltd. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,482 shares of the biopharmaceutical company’s stock after purchasing an additional 1,122 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Regeneron Pharmaceuticals were worth $11,278,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Meritage Portfolio Management purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $6,014,000. CWM LLC raised its stake in shares of Regeneron Pharmaceuticals by 770.0% in the second quarter. CWM LLC now owns 35,506 shares of the biopharmaceutical company’s stock worth $18,641,000 after purchasing an additional 31,425 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 7.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 10,853 shares of the biopharmaceutical company’s stock worth $5,699,000 after purchasing an additional 792 shares during the last quarter. Concurrent Investment Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 136.4% in the second quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 936 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 11.3% in the second quarter. Fifth Third Wealth Advisors LLC now owns 1,511 shares of the biopharmaceutical company’s stock worth $793,000 after purchasing an additional 154 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $564.63 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business has a fifty day simple moving average of $573.95 and a two-hundred day simple moving average of $564.51. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The company has a market capitalization of $59.84 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research report on Monday, August 4th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $817.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.